Dechert Advises Abivax on Largest-ever Nasdaq IPO for a French Biotech

Dechert advised French biotech Abivax in connection with its successful IPO on the Nasdaq Global Market (“Nasdaq”) for approximately €223.3 million (US$235.8 million). The transaction is the largest Nasdaq IPO ever carried out by a French biotech company.

The proceeds from the transaction will primarily allow Abivax to fund the development of obefazimod, its most advanced drug candidate, in ulcerative colitis and other chronic inflammatory diseases.

Dechert’s Paris-based corporate/life sciences team was led by partner Alain Decombe and associate Vianney Toulouse, who were assisted by associates Mathilde Duchamp and Sabrine Maaroufi.

Dechert has served as legal counsel to Abivax for many years, and this year alone has advised on three financing transactions with a combined total of more than €500 million.

About Dechert

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.